Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


T. M. Bukatina has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Post-marketing pharmacovigilance methods: Spontaneous reports and scientifi c literature monitoring (review)

    by T. M. Bukatina

    INTRODUCTION. Many aspects of the drug safety profile, including rare and delayed adverse drug reactions (ADRs), are identified only in the post-marketing period when the drug is used in real-world clinical practice. However, the drawbacks inherent in spontaneous reporting and scientific literature monitoring (the main methods of post-marketing pharmacovigilance), such as incompleteness, fragmentation, variability in data quality, and the lack of standardized approaches to their analysis necessitate the systematization of information and the unification of approaches to data processing. AIM. To systematize information on the spontaneous reporting method and scientific literature monitoring, as well as on data processing approaches in post-marketing pharmacovigilance for risk management and ensuring drug safety. DISCUSSION . Spontaneous reporting is the basic passive method for post-marketing drug safety monitoring, with advantages including broad population coverage and the ability to detect a wide range of ADRs, including rare, delayed, and previously unknown ones. The effectiveness of the spontaneous reporting method can be enhanced through the development of educational programs for healthcare professionals and patients, the implementation of natural language processing (NLP) technologies to automate the extraction of structured information about ADRs from unstructured text sources, and integration with real-world data (RWD) to confirm signals and quantify risks. Scientific literature monitoring serves as a bridge between the passive collection of real-world data and evidence-based findings from controlled studies. An analysis of the EAEU Good Pharmacovigilance Practice Guidelines shows that when searching for information in the scientific literature, special aspects of the drug safety profile must be taken into account: effects on pregnancy outcomes, use in pediatrics, lack of efficacy, overdose, off-label use, and preclinical data. To standardize statistical methods for signal detection and the correct interpretation of signals (disproportionality analysis in spontaneous reporting databases), the READUS-PV guideline (2024) is recommended. CONCLUSIONS. The modern methodology of post-marketing pharmacovigilance is a dynamically evolving system. The presented systematization of approaches to spontaneous reporting and scientific literature monitoring, as well as the list of mandatory drug safety aspects, can serve as a practical tool for specialists in planning and conducting drug safety assessments.


  • Open Access

    Risk Assessment Algorithms in Pharmacovigilance: A Review

    by T. M. Bukatina

    INTRODUCTION. In the Russian Federation, risk-based approaches/methods to assess the safety of medicinal products have been used since 2016, but existing models based on them are few and applicable mainly to healthcare organizations. This underscores the need to systematise risk assessment procedures for medicinal products within pharmacovigilance frameworks by pharmacovigilance specialists using a risk-based approach in the risk management system.AIM. This study aimed to analise of the key tools of the risk-based approach and optimise their application in medicinal product risk management systems.RESULTS. A four-stage risk management framework for medicinal products was developed using a risk-based methodology: identification of risks associated with medicinal product use, determination of risk factors specific to individual medicinal products, correlation and evaluation of data for each risk factor with each of the identified risks and a conclusion on the benefit-risk ratio of medicinal products use. Key tools for implementing this approach include: 1) organization of work with information about adverse drug reactions; 2) active monitoring of drug safety; 3) development, implementation, and evaluation of risk mitigation measures; 4) targeted communication of safety issues to healthcare professionals, patients, and caregivers. Spontaneous reports, reports of adverse drug reactions received on request from the holder of the registration certificate, data from pharmacoepidemiological studies, information published in the scientific medical literature, as well as Internet resources are used as sources of information to identify the risks of adverse drug reactions at the post-registration stage of medicinal products circulation. Risk factors for the development of adverse drug reactions in the use of medicinal products are physiological changes in the patient's body, gender, age, presence of comorbidities, genetic predisposition, differences in pharmacokinetics and pharmacodynamics of medicinal products depending on the patient's age, use of off-label medicinal products. A five-step algorithm for medicinal product risk assessment was developed: parameters and objectives of risk evaluation, data sources, potential risks, severity and probability of risks, and benefit-risk ratio assessment. Additional risk minimisation measures are summarised.CONCLUSIONS. The proposed variant of the risk-based approach using available tools can be used by pharmacovigilance specialists in drug risk management.


  • Risk Management Plan: Expert Review of Applications for Marketing Authorisation in the EAEU Depending on the Type of Medicinal Product (Review)

    by T. M. Bukatina, E. V. Shubnikova

    INTRODUCTION. A risk management plan (RMP) is an important document for assessing and managing risks when using a medicinal product. An RMP is provided as part of the marketing authorisation application for a medicinal product. The requirements for the need to submit an RMP and the information in its sections depend on the type of medicinal product and marketing authorisation procedure. Marketing authorisation holders will benefit from an expert systematisation of the requirements for RMP submission outlined in the Eurasian Economic Union (EAEU) Rules for Marketing Authorisation and Expert Assessment of Medicinal Products for Human Use and Rules of Good Pharmacovigilance Practice (Eurasian Economic Commission Council Decisions Nos. 78 and 87 dated 03.11.2016, respectively), as this systematisation will contribute to a more accurate drafting of RMPs.AIM. This study aimed to analyse the requirements for submitting parts and modules of an RMP depending on the type of medicinal product being authorised according to the EAEU marketing authorisation procedures.RESULTS. This review analyses and systematises the requirements for the development of an RMP and the submission/non-submission of its main parts (I–VI) and Part II modules (CI–CVIII) depending on the type of medicinal product and marketing authorisation procedure. The article describes the principles for providing information in three main RMP sections: Safety Specifications (Part II), Pharmacovigilance Plan (Part III), and Risk Minimisation Measures (Part V). Flow charts illustrate summarised information on pharmacovigilance activities and risk minimisation measures that is included in an RMP. The article systematises the considerations for the analysis and evaluation of information for the main parts (I–VI) and Part II modules (CI–CVIII) of an RMP.CONCLUSIONS. The systematisation of the requirements of Eurasian Economic Commission Council Decisions Nos. 78 and 87 dated 03.11.2016, as well as the expert comments on considerations for RMP submission depending on the type of medicinal product and marketing authorisation procedure will help to improve the quality of RMPs and, in general, the safety of medicinal products authorised in the EAEU.


  • Open Access

    Bempedoic Acid: Safety and Efficiacy of a New Lipid-Lowering Agent

    by I. A. Mazerkina, T. V. Bukatina, T. V. Aleksandrova

    Scientific relevance. Lowering low-density lipoprotein cholesterol (LDL-C) levels with statins is a generally accepted standard treatment for dyslipidaemia. However, adverse reactions and intolerance to statins have motivated the search for lipid-modifying agents with alternative mechanisms of action. Bempedoic acid is one of these alternative agents.Aim. The study aimed to review published data on the mechanism of action, pharmacokinetics, pharmacodynamics, safety and efficacy of bempedoic acid used as a lipid-lowering agent.Discussion. Similar to statins, bempedoic acid inhibits cholesterol synthesis from acetyl-CoA. Statins and bempedoic acid differ in their mechanisms of action mainly because the conversion of bempedoic acid into its active metabolite takes place only in the liver. As a result, bempedoic acid does not cause adverse drug reactions in muscles. The main safety and efficacy data on bempedoic acid were obtained in phase III CLEAR trials. Compared to placebo, bempedoic acid reduced LDL-C levels by an additional 18% in combination with maximum tolerated doses of statins and by 25% in monotherapy in patients with statin intolerance. In the CLEAR Outcomes trial, long-term treatment with bempedoic acid reduced the risk of major adverse cardiovascular events in patients with statin intolerance (n=13970) by 13%. A slight increase in gout attack frequency was observed, primarily in patients with pre-existing hyperuricaemia.Conclusions. Therefore, bempedoic acid is a safe and effective treatment option for patients with dyslipidaemia at high risk of atherosclerotic cardiovascular disease. It can be used either in combination with statins or, in the case of statin intolerance, as monotherapy and with ezetimibe.


  • Open Access

    Risk Management Plan: An Expert Analysis of Changes to the EAEU Good Pharmacovigilance Practice Requirements for the Content and Submission of the Document

    by T. M. Bukatina, E. V. Shubnikova

    План управления рисками: экспертный анализ изменений требований Правил надлежащей практики фармаконадзора ЕАЭС к содержанию и порядку представления документа


  • Open Access

    Safety of Antibacterial and Antiprotozoal Medicinal Products

    by E. V. Shubnikova, T. M. Bukatina, A. A. Druzhinina, E. O. Zhuravleva, G. V. Kutekhova, N. Yu. Velts, Н. Ю. Вельц

    The experts of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on the recalls of antibacterial and antiprotozoal medicinal products and/or the need for labelling updates due to changes in the safety profile. The analysis revealed 16 decisions containing information on the following medicines registered in Russia: ertapenem, сeftriaxone, cefazolin, аmoxicillin, сefoperazone+sulbactam, piperacillin+tazobactam, сlindamycin, teicoplanin, rifampin, co-trimoxazole, hydroxychloroquine.


  • Open Access

    Ivermectin: Evaluation of Efficacy and Safety in COVID-19

    by E. V. Shubnikova, N. A. Susekova, T. M. Bukatina, M. S. Galenko, A. A. Druzhinina

    The search for an effective and safe COVID-19 therapy involves, among other things, assessment of efficacy of medicines already used for the treatment of other diseases, and having potential antiviral activity against SARS-CoV-2. The relevance of the presented study stems from ambiguous data on the off-label use of the antiparasitic medicine ivermectin for the treatment of COVID-19 patients. The aim of the study was to analyse ivermectin efficacy and safety for COVID-19 treatment, as reflected in the scientific literature. Ivermectin, an antiparasitic medicine from the group of macrocyclic lactones produced byStreptomyces avermitilis, stimulates release of the inhibitory neurotransmitter gamma-aminobutyric acid, which leads to impaired transmission of nerve impulses, paralysis and death of parasites. The results of preclinical studies show ivermectin’s inhibitory activity against a number of RNA and DNA viruses, including SARS-CoV-2. The results of ivermectin clinical studies are ambiguous: a number of studies demonstrated a positive effect on the condition of COVID-19 patients, however, there is currently no convincing evidence of the validity and efficacy of ivermectin use for the prevention and treatment of COVID-19 patients. The safety profile of ivermectin is relatively favourable. Large randomised controlled trials are needed to fully assess the feasibility of using ivermectin in COVID-19.


  • Open Access

    Critical Overview of the Contents of Risk Management Plans for Medicines

    by T. M. Bukatina, E. V. Shubnikova

    The pharmacovigilance system plays one of the key roles in ensuring safety and efficacy of medicine use. The risk management process helps to ensure the most favourable benefit/risk ratio of a medicine or combination of medicines both for the target populations and the general public. Unavailability of a risk management process for medicines may adversely affect the health of the general population. One of the major documents in medicine risk management is the risk management plan (RMP).The aim of the study was to analyse compliance of RMPs submitted as part of registration dossiers with the requirements of the Eurasian Economic Union (EAEU), and to analyse problems arising during their preparation.Materials and methods: the authors analysed 200 RMPs submitted from January 1 until August 31, 2021.Results: it was determined that the most frequent mistakes made by pharmacovigilance officers are related to medicine summaries in RMPs covering several medicines, medicine safety specification parts of RMPs, description of risks in the pharmacovigilance plan and description of risk minimisation measures, and insufficient representation of the key elements of the medicine efficacy and safety overview in the RMP summary. For instance, RMPs often lack information on the epidemiology of indications for target populations in the EAEU, or RMPs may lack some of the major risks reflected in the patient information leaflets, or lack assessment of safety risk minimisation actions, etc.Conclusions: proper preparation of RMPs that would comply with the EAEU Good Pharmacovigilance Practice is inconceivable without further professional training of pharmacovigilance officers.


  • Open Access

    Drug Safety Monitoring—International Information

    by E. V. Shubnikova, T. M. Bukatina, G. V. Kutekhova

    Experts of the Department for Evaluation of Medicinal Products’ Safety of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on limiting the use of some medicinal products and/or the need to introduce changes in patient information leaflets due to changes in the medicines’ safety profiles. The analysis helped to identify 16 administrative decisions that contain information on the following medicines registered in Russia: duloxetine, sertraline, paroxetine, сitalopram, desvenlafaxine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, venlafaxine, vortioxetine, mirtazapine, risperidone, clozapine, aripiprazole, quetiapine, olanzapine, lacosamide, gabapentin, pregabalin.


  • Open Access

    Comparative Analysis of International Databases of Adverse Drug Reactions

    by A. S. Kazakov, M. A. Darmostukova, T. M. Bukatina, N. Yu. Velts, R. N. Alyautdin, Н. Ю. Вельц

    In 1968 the World Health Organisation initiated the development of an international programme for collection of data from the maximum number of sources about potential adverse effects of medicines. In order to implement this programme, a number of databases were created, such as the global database VigiBase, the European database EudraVigilance, and the database of the Eurasian Economic Union (EAEU). The aim of the present study was to compare approaches of the international spontaneous reports databases to collection, processing, and analysis of information on adverse drug reactions. It was demonstrated that the international databases VigiBase, EudraVigilance, and the EAEU database of adverse drug reactions contain different numbers of spontaneous reports, but serve the same objectives, namely to collect, process, and analyse information submitted as spontaneous reports. Unlike VigiBase that contains reports on authorised medicines coming from the national pharmacovigilance centres only, EudraVigilance also receives data from marketing authorisation holders and has reports on adverse drug reactions observed during clinical trials. The exchange of information between countries ensures rapid identification of safety signals concerning potential risks of medicines, and increases the likelihood of detecting rare and late-onset adverse reactions that may go unnoticed when analysing national data in a particular country. Spontaneous reports databases are an essential tool of the international drug safety monitoring community. Effective measures in this area will ultimately help to improve patients’ health and quality of life.